Rempart Asset Management Inc. Sells 1,197 Shares of Thermo Fisher Scientific Inc. $TMO

Rempart Asset Management Inc. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 51,953 shares of the medical research company’s stock after selling 1,197 shares during the quarter. Thermo Fisher Scientific makes up approximately 5.7% of Rempart Asset Management Inc.’s investment portfolio, making the stock its 2nd largest position. Rempart Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $30,104,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. National Wealth Management Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $227,000. Tilia Fiduciary Partners Inc. grew its position in Thermo Fisher Scientific by 3.8% during the fourth quarter. Tilia Fiduciary Partners Inc. now owns 4,862 shares of the medical research company’s stock valued at $2,818,000 after buying an additional 177 shares during the period. Sax Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 2.7% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,716 shares of the medical research company’s stock valued at $994,000 after buying an additional 45 shares in the last quarter. Czech National Bank boosted its stake in shares of Thermo Fisher Scientific by 3.3% during the 4th quarter. Czech National Bank now owns 99,069 shares of the medical research company’s stock worth $57,406,000 after acquiring an additional 3,163 shares in the last quarter. Finally, Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. The trade was a 1.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TMO shares. Barclays upped their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a report on Friday, January 30th. The Goldman Sachs Group began coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price objective for the company. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Evercore restated an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $633.68.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $490.64 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. The stock’s 50 day simple moving average is $535.73 and its 200-day simple moving average is $547.85. The company has a market cap of $182.27 billion, a PE ratio of 27.66, a price-to-earnings-growth ratio of 2.83 and a beta of 0.96. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating the consensus estimate of $6.45 by $0.12. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned $6.10 EPS. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be paid a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, March 13th. Thermo Fisher Scientific’s payout ratio is 10.60%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.